AbbVie - A practical guide to use of JAK inhibitors in the management of RA and SpA


Industry room 2

Satellite Symposia
02 June 2021 18:15 - 19:45

Learning Objective(s): 
  • To provide audience members with educational content on how to manage RA and SpA patients with JAK-inhibitors (JAKi) as per their approved EMA labels.
  • To acknowledge the safety “hot topic” questions of interest that HCPs have on RA and SpA management with JAKi medications.
  • To inform audience on how to interpret safety analysis data from RCTs, and how to interpret safety data in the clinical context.
  • To describe case-based, data-driven examples of how to manage RA and SpA patient with JAKi under specific circumstances, using data available from approved JAKi medications.

Presentations

Title Time Calendar .ics
Elevating RA and SpA standard of care: The emerging role of JAK inhibitors
02 June 2021 18:15 - 18:25 .ics
Understanding and managing infections
02 June 2021 18:25 - 18:40 .ics
The who, what, where and why of Herpes Zoster
02 June 2021 18:40 - 18:55 .ics
MACE and Venous thromboembolism in RA and SpA: What should we be considering?
02 June 2021 18:55 - 19:10 .ics
Malignancies and RA and SpA: From risk factors to disease management
02 June 2021 19:10 - 19:20 .ics
Panel Discussion and Q&A
02 June 2021 19:20 - 19:40 .ics
Signal to noise ratio: Understanding the benefits and risks of JAK inhibitors
02 June 2021 19:40 - 19:45 .ics